| Net (Loss) Income Per Share |
NET (LOSS) INCOME PER SHARE The following table presents the computation of basic and diluted net (loss) income per share for the three and nine months ended June 30, 2026 and 2025. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Nine Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | | (in thousands, except per share amounts) | | Numerator: | | | | | | | | | | Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. | | $ | (194,280) | | | $ | (175,241) | | | $ | (296,205) | | | $ | 22,119 | | | | | | | | | | | | Denominator: | | | | | | | | | Weighted-average basic shares outstanding (1) | | 143,378 | | | 139,039 | | | 141,331 | | | 132,385 | | | Effect of dilutive securities | | — | | | — | | | — | | | 967 | | Weighted-average diluted shares outstanding (1) | | 143,378 | | | 139,039 | | | 141,331 | | | 133,352 | | | | | | | | | | | | Basic net (loss) income per share | | $ | (1.36) | | | $ | (1.26) | | | $ | (2.10) | | | $ | 0.17 | | | Diluted net (loss) income per share | | $ | (1.36) | | | $ | (1.26) | | | $ | (2.10) | | | $ | 0.17 | |
(1) Include shares of common stock into which the 2024 and 2026 Avoro Pre-Funded Warrants may be exercised. See Note 6. The following table sets forth the number of potentially dilutive securities that have been excluded from the calculation of diluted net (loss) income per share because to include them would be anti-dilutive. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Nine Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | | (in thousands) | | Options | | 830 | | | 768 | | | 830 | | | 756 | | | Restricted stock units | | 5,795 | | | 5,178 | | | 5,795 | | | 4,770 | | | If-converted common stock from convertible notes | | 8,039 | | | — | | | 8,039 | | | — | | | Total | | 14,664 | | | 5,946 | | | 14,664 | | | 5,526 | |
|